CD33_PGX6_score predicts gemtuzumab ozogamicin response in childhood acute myeloid leukemia: A report from the Children’s Oncology Group

Lata Chauhan, Miyoung Shin, Yi Cheng Wang, Michael Loken, Jessica Pollard, Richard Aplenc, Betsy A. Hirsch, Susana Raimondi, Rhonda E. Ries, Irwin D. Bernstein, Alan S. Gamis, Todd A. Alonzo, Soheil Meshinchi, Jatinder K Lamba

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


PURPOSE The US Food and Drug Administration recently announced reapproval of gemtuzumab ozogamicin (GO) for treatment of CD33-positive acute myeloid leukemia (AML), thus opening up opportunities to develop strategies for effective use of GO. In light of our recent report showing prognostic significance of CD33 splicing single nucleotide polymorphisms (SNPs), the objective of this study was to comprehensively evaluate CD33 SNPs for accurate prediction of patients with AML who are more or less likely to respond to GO. PATIENTS AND METHODS We investigated the five new CD33 SNPs (rs2455069, rs35112940, rs61736475, rs1803254, and rs201074739) for association with CD33 leukemic cell surface expression and clinical response in pediatric patients with AML enrolled in the Children’s Oncology Group AAML0531 trial. We further developed a composite CD33 pharmacogenetics (PGx) score using six CD33 SNPs (CD33_PGx6_score) for association with clinical outcome. RESULTS Four CD33 SNPs were associated with cell surface CD33 levels and clinical response in the GO versus no-GO arms. Therefore, the CD33_PGx6_score was built using directional genotype scores for the previously reported splicing SNP and five new SNPs. Patients with a CD33_PGx6_score of 0 or higher had higher CD33 expression levels compared with patients with a score of less than 0 (P, .001). In addition, patients with a score of 0 or higher demonstrated an improved disease-free survival in the GO versus no-GO arms (62.5% 6 7.8% v 46.8% 6 8.3%, respectively; P = .008) and a reduced risk of relapse (28.3% 6 7.2% v 49.9% 6 8.4%, respectively; P, .001). No improvement from GO was observed in patients with a CD33-PGx6_score of less than 0. Consistent results were observed across the risk groups. CONCLUSION In this study, we report a composite CD33_PGx6_score using directional genotype scores of CD33 SNPs. Once validated, our findings hold promise for use of the CD33_PGx6_score to guide efficient use of GO in patients with AML. In addition, because the CD33_PGx6_score considers SNPs with varying abundance in different ethnic groups, it has potential for global application.

Original languageEnglish (US)
Pages (from-to)1-15
Number of pages15
JournalJCO Precision Oncology
StatePublished - 2019

Bibliographical note

Publisher Copyright:
© 2019 by American Society of Clinical Oncology


Dive into the research topics of 'CD33_PGX6_score predicts gemtuzumab ozogamicin response in childhood acute myeloid leukemia: A report from the Children’s Oncology Group'. Together they form a unique fingerprint.

Cite this